29 GLP-1 Statistics for Women 2027

Current data on how women are using GLP-1 medications, from prescription trends and treatment adherence to side effects, healthcare access, and considerations for midlife weight management.

Short answer

Women use GLP-1 medications more than men: 11.9% of women versus 7.6% of men reported past-year use in a 2025 US survey, and one in five women ages 50 to 64 reported having used a GLP-1 agonist. Staying on treatment is the main challenge, with 14.8% of patients persisting for two years in one commercially insured US cohort.

Majesta HealthReviewed by Ksenia Petrushkina, PA-C
Published Reviewed 16 min read

Current data on how women are using GLP-1 medications, from prescription trends and treatment adherence to side effects, healthcare access, and considerations for midlife weight management.

Women are reshaping the GLP-1 medication landscape. From treatment adoption to healthcare access, the numbers tell a clear story: 11.9% of women reported using GLP-1 medications during the previous year, compared with 7.6% of men.

This gender gap reflects differences in treatment use and access. For women seeking weight management support, understanding these statistics can inform decisions about medication selection, physician-guided care, and provider choice.

Key Takeaways

  • Women lead GLP-1 usage: 11.9% of women versus 7.6% of men reported past-year use in a 2025 U.S. survey.
  • Peak adoption occurs in midlife: One in five women aged 50 to 64 reported having used GLP-1 agonists.
  • Private prescribing shows a gender gap: In England, 79.4% of patients receiving private GLP-1 prescriptions for obesity in one provider's dataset were women.
  • Adherence remains a challenge: Only 14.8% of patients persisted with treatment over two years in a commercially insured U.S. cohort without diabetes.
  • Gastrointestinal side effects are common: Clinical trials of FDA-approved Wegovy reported nausea in 44% of participants receiving the studied medication.
  • Access disparities persist: Private prescription rates were 32% lower in England's most deprived areas than its least deprived areas in one provider's data.

Understanding GLP-1 Drugs for Weight Loss: Usage Trends

GLP-1 receptor agonists have transformed from a diabetes treatment category into an important option in weight management. Women account for a substantial share of patients using these medications.

1. Approximately 9.8% of U.S. adults used GLP-1 medications in the past year

GLP-1 adoption has expanded across the United States. A CDC survey conducted in July and August 2025 found that 9.8% of adults reported using a GLP-1 medication during the previous year.

The survey included adults using GLP-1 medications for different medical indications, not exclusively weight management.

This distinction matters when interpreting national adoption rates because diabetes treatment and obesity treatment contribute to overall GLP-1 usage.

2. About 11.9% of U.S. women reported GLP-1 use

Women reported higher medication use than men in the CDC's 2025 survey. Approximately 11.9% of female respondents had used a GLP-1 medication during the previous year.

The finding includes women using treatment for diabetes and other medical indications, alongside weight management.

These figures demonstrate how widely GLP-1 medications are being used among women across different healthcare needs.

3. About 7.6% of U.S. men reported GLP-1 use

The same CDC survey found that 7.6% of male respondents had used GLP-1 medications during the previous year.

This represents a lower reported usage rate than among women, although the survey does not establish why the difference exists.

Gender differences may also vary depending on whether researchers examine diabetes prescriptions, obesity treatment, or medication use for other conditions.

4. GLP-1 use reached 13.7% among adults aged 40 to 64

Midlife adults represent an important GLP-1 user population. The CDC found that 13.7% of adults aged 40 to 64 reported past-year medication use.

This age group includes many women navigating perimenopause and menopause, although the survey did not specifically attribute treatment use to hormonal changes.

The results reflect medication use for multiple indications and should not be interpreted as menopause-specific prescribing data.

5. GLP-1 use reached 24.1% among adults with severe obesity

Medication usage varies substantially by body weight category. In the CDC's 2025 survey, 24.1% of adults with class 3 obesity reported past-year GLP-1 use.

Higher usage was observed among adults with greater body mass index categories.

However, BMI alone does not determine medication appropriateness. Individual eligibility depends on a licensed prescribing clinician's assessment.

PopulationPast-year GLP-1 useSurvey period
All U.S. adults9.8%July–August 2025
Women11.9%July–August 2025
Men7.6%July–August 2025
Adults aged 40–6413.7%July–August 2025

Women's GLP-1 Usage: The Gender Gap in Weight Management

Research consistently identifies substantial differences in GLP-1 adoption across age groups and between women and men.

6. About 11.8% of U.S. adults had ever used GLP-1 agonists

A RAND American Life Panel survey conducted in April and May 2025 found that 11.8% of respondents had taken a GLP-1 agonist at least once.

This measure captures previous use rather than only current treatment.

Participants were asked about medication use for weight loss or chronic conditions, including diabetes and heart disease.

7. One in five women aged 50 to 64 had used GLP-1 agonists

Women aged 50 to 64 recorded the highest usage rate among the demographic groups examined. RAND found that 20% of women in this age range had used GLP-1 medications.

This age group overlaps with the perimenopausal and menopausal years.

However, the study did not establish menopause as the reason for higher medication use among these women.

8. GLP-1 usage reached 15.1% among women aged 30 to 49

Women in their thirties and forties also reported substantial usage. RAND found that 15.1% of women aged 30 to 49 had used GLP-1 medications.

The findings demonstrate that medication adoption extends beyond the menopausal age range.

These results include treatment for chronic medical conditions and should not be interpreted exclusively as weight-loss medication use.

9. About 7.2% of men aged 30 to 49 had used GLP-1 agonists

The gender gap was pronounced among adults aged 30 to 49. RAND reported 7.2% usage among men compared with 15.1% among women.

Women in this age group were therefore more than twice as likely to report previous GLP-1 use.

The survey measured reported medication experience rather than underlying differences in clinical eligibility.

10. Another 14% of U.S. adults expressed interest in GLP-1 treatment

Interest extends beyond people who have already started medication. RAND found that 14% of respondents had not used GLP-1 agonists but expressed interest in taking them.

The survey distinguished this group from respondents who had previously used treatment.

Expressing interest does not establish medical eligibility or indicate that respondents will eventually receive a prescription.

Private GLP-1 Prescribing Trends Among Women

International prescribing data provides additional context. A February 2026 Health Foundation analysis examined 113,630 patients receiving prescriptions through one private weight-management provider in England.

11. Women represented 79.4% of private GLP-1 patients in an England dataset

The Health Foundation found that 79.4% of patients receiving private prescriptions for obesity were women.

The analysis covered prescriptions issued between November 2024 and October 2025.

These findings describe one provider's patients in England rather than all private prescriptions across the United Kingdom or internationally.

12. Prescription rates reached 578 per 100,000 women aged 30 to 49

The gender gap was particularly pronounced during prime working and child-rearing years. England's provider data showed 578 prescriptions per 100,000 women aged 30 to 49.

Women in this age group recorded substantially higher prescribing rates than their male counterparts.

The analysis measured prescriptions through one private provider and did not capture every treatment pathway available in England.

13. Men aged 30 to 49 recorded 166 prescriptions per 100,000

Among men aged 30 to 49, the corresponding rate was 166 per 100,000 in the same private provider dataset.

This translated into approximately 3.5 women receiving prescriptions for every man in this age group.

The findings describe private weight-management prescribing rather than all GLP-1 use for diabetes and other conditions.

14. Adults aged 30 to 39 represented 27.2% of private GLP-1 patients

The Health Foundation analysis found that 27.2% of patients in the private provider dataset were aged 30 to 39.

This was the largest age category examined in the analysis.

These figures reflect the age distribution within one provider's patient population, not the percentage of all adults aged 30 to 39 receiving medication.

15. Adults aged 40 to 49 represented 24.3% of private GLP-1 patients

Patients aged 40 to 49 accounted for another 24.3% of prescriptions in the dataset.

Together, adults in their thirties and forties represented a substantial proportion of private weight-management patients.

The concentration reflects the provider's patient demographics and should not be generalized to every healthcare system.

GLP-1 Access Disparities: Who Receives Treatment?

Socioeconomic factors significantly influence who can access GLP-1 medications. Private treatment availability and affordability remain important considerations for women evaluating their options.

16. Private prescription rates were 32% lower in England's most deprived areas

The access gap persists across geographic regions. The Health Foundation found 32% lower prescription rates in the most deprived areas compared with the least deprived.

The analysis focused on private prescriptions from one provider.

These differences suggest that private treatment access is not distributed evenly across socioeconomic groups.

17. Around 45% of patients in deprived areas had a starting BMI of 35 or higher

Patients accessing treatment in lower-income areas tended to have a higher starting BMI. Approximately 45% of patients aged 30 to 49 in the most deprived areas had a BMI of at least 35.

The corresponding proportion in the least deprived areas was approximately 30%.

These findings indicate differences in patients' starting weight categories but cannot establish when or why individual patients sought treatment.

England private prescribing measureFindingPopulation
Female patients79.4%All patients studied
Women aged 30–49578 per 100,000Women in age group
Men aged 30–49166 per 100,000Men in age group
Prescription disparity32% lowerMost vs. least deprived areas

GLP-1 Usage Among Adults With Diabetes

Diabetes remains a primary indication for GLP-1 medication use. National health surveys provide additional evidence about treatment patterns across demographic groups.

18. About 26.5% of adults with diagnosed diabetes used injectable GLP-1 medications

The CDC's 2024 National Health Interview Survey found that 26.5% of adults with diagnosed diabetes used injectable GLP-1 medications.

The survey measured injectable treatments used to lower blood sugar or manage weight.

These findings are specific to adults with diagnosed diabetes and should not be generalized to people using GLP-1 medications exclusively for obesity.

19. GLP-1 injectable usage reached 27.2% among women with diagnosed diabetes

Women with diagnosed diabetes reported substantial injectable GLP-1 use. The CDC found that 27.2% of women in this population used these medications in 2024.

However, the difference between women and men with diagnosed diabetes was not statistically significant.

This differs from broader surveys that found higher overall GLP-1 usage among women across multiple medical indications.

20. One-third of adults aged 50 to 64 with diagnosed diabetes used GLP-1 injectables

For adults with diagnosed diabetes, usage rates climbed even higher in midlife. The CDC reported 33.3% usage among adults aged 50 to 64.

This was higher than the reported usage among adults aged 65 and older.

The findings concern injectable GLP-1 medications among adults with diagnosed diabetes, not menopause-related weight management specifically.

21. About 32.4% of adults with diabetes and obesity used GLP-1 injectables

Body weight was associated with GLP-1 treatment patterns. Among adults with diagnosed diabetes and obesity, 32.4% used injectables in 2024.

Use was lower among respondents in the overweight and healthy-weight BMI categories.

The survey demonstrates how medication use differs across weight categories without establishing individual treatment eligibility.

GLP-1 Side Effects: What Women Should Expect

Understanding potential side effects helps women prepare for treatment and know when to contact their healthcare provider. Most commonly reported adverse reactions are gastrointestinal.

The following clinical-trial figures apply specifically to FDA-approved Wegovy, not compounded semaglutide or tirzepatide preparations.

22. Nausea affected 44% of adults receiving Wegovy in clinical trials

Nausea was the most commonly reported gastrointestinal side effect in adult trials of FDA-approved Wegovy. The prescribing information reported nausea in 44% of participants receiving the studied treatment.

The corresponding rate among placebo recipients was 16%.

These trial findings describe a specific FDA-approved semaglutide product and cannot establish nausea rates for compounded preparations.

23. Diarrhea affected 30% of adults receiving Wegovy

Gastrointestinal symptoms were common during treatment. Adult Wegovy trials reported diarrhea in 30% of treated participants.

The corresponding rate among placebo recipients was 16%.

Persistent diarrhea can contribute to dehydration and requires medical attention when severe or accompanied by other concerning symptoms.

24. Vomiting affected 24% of adults receiving Wegovy

Vomiting was another frequently reported gastrointestinal adverse reaction. The 2024 Wegovy prescribing information listed vomiting in 24% of treated adults.

The corresponding placebo rate was 6%.

Women experiencing persistent vomiting should contact their prescribing clinician, particularly if they cannot maintain adequate fluid intake.

Adverse reactionWegovy groupPlacebo group
Nausea44%16%
Diarrhea30%16%
Vomiting24%6%
Constipation24%11%

Treatment Adherence and Persistence: The Continuation Challenge

Long-term medication adherence remains one of the biggest challenges in GLP-1 treatment. These statistics highlight why ongoing physician support and accessible care models matter.

25. Women represented 81% of participants in a two-year obesity treatment study

Long-term treatment research reflects the broader usage pattern. A 2024 analysis of commercially insured adults without diabetes found that 81% of participants were women.

The study included 3,364 patients who initiated GLP-1 treatment in 2021.

The findings describe this specific insured cohort rather than the gender distribution of everyone receiving GLP-1 medications.

26. Only 47.1% of patients remained on treatment at 180 days

Treatment continuation declined substantially during the first six months. Persistence fell to 47.1% at 180 days in the study population.

Researchers defined persistence using prescription claims and treatment gaps.

The data did not establish that every discontinuation resulted from side effects, cost, or problems accessing medication.

27. About 28.9% remained on treatment at one year

The one-year mark showed further decline. 28.9% of patients met the study's treatment-persistence definition after twelve months.

This measure reflected continued prescription coverage without a qualifying treatment gap.

The findings demonstrate challenges with treatment continuation among commercially insured adults receiving obesity treatment.

28. Only 14.8% persisted with GLP-1 treatment at two years

Long-term continuation was relatively uncommon. Researchers found that 14.8% of patients remained persistent with treatment over two years.

Persistence measured whether patients continued therapy without exceeding the study's permitted prescription gap.

This differs from adherence, which evaluates the proportion of days patients had medication available.

29. Only 16.6% met adherence standards over two years

Adherence, measured by proportion of days covered, also remained low. The study found that 16.6% of patients achieved the required adherence threshold.

Researchers classified patients as adherent when medication coverage reached at least 80% of the observation period.

This distinction is important because adherence and treatment persistence measure different aspects of medication continuation.

Women's Health Considerations: GLP-1 Use During Perimenopause and Menopause

The concentration of GLP-1 usage among women in their 40s through 60s overlaps with the hormonal transitions many women experience during these years.

Several factors may influence midlife weight management:

  • Hormonal shifts affect metabolism: Declining estrogen levels can alter how the body stores and processes fat.
  • Weight distribution changes: Many women notice increased abdominal fat during menopause.
  • Traditional approaches may become less effective: Strategies that worked earlier in life may produce different results as age and health circumstances change.
  • Health risks increase: Age-related changes in body composition can contribute to cardiovascular and metabolic risk.

For women experiencing menopause-related weight gain, GLP-1 medications represent one possible treatment option when clinically appropriate.

However, higher medication use among midlife women does not establish that GLP-1 medications specifically treat menopause or its underlying hormonal changes.

Accessing GLP-1 Medications Online: What Women Need to Know

Telehealth provides another pathway to physician evaluation and ongoing care. However, the quality and legitimacy of online providers vary considerably.

Women evaluating telehealth options should look for licensed physician oversight, verifiable credentials, appropriate pharmacy licensing, transparent pricing, and clear medication disclosures.

Majesta Health is a LegitScript-certified, women-centered telehealth platform connecting patients with independent U.S.-licensed physicians. Its named pharmacy partners include Belmar Pharma Solutions and Strive Pharmacy.

Majesta's Essential plan is priced at $159 for the first month, then $289/month. Its Performance plan costs $269 for the first month, then $399/month, per official pricing details on the website on November 20,2026.

The planned Express option has proposed pricing of $249 for the first approved 30-day care cycle, followed by $339 per approved care cycle. It is not yet available for enrollment.

The plans include physician care, medication if prescribed, and shipping. Enrollment had not opened as of November 16, 2026, and nothing is charged until physician approval.

Compounded GLP-1 Medications: Understanding the Options

Compounded medications may be considered when a licensed prescribing clinician identifies a patient-specific medical need that cannot be met by an FDA-approved medication.

These preparations are subject to different regulatory requirements from FDA-approved manufactured products.

Compounded medications are not FDA-approved as final products and are not generic versions of, equivalent to, or interchangeable with any FDA-approved medication.

The FDA explains that compounded drugs do not undergo its premarket evaluation for safety, effectiveness, and quality.

Clinical trial outcomes and side-effect percentages for FDA-approved semaglutide and tirzepatide products should not be applied to compounded formulations.

What the GLP-1 Statistics Mean for Women: How Majesta Supports Informed Care

The latest GLP-1 statistics show that women represent a substantial share of medication users, particularly during midlife. They also reveal persistent challenges involving healthcare access, treatment continuation, and medication-related side effects.

For women exploring weight management, these findings highlight the importance of choosing care based on medical suitability rather than popularity or treatment trends.

Majesta focuses on helping women navigate these decisions through transparent information and physician-guided evaluation.

Its approach includes:

  • Licensed physician evaluation: Independent U.S.-licensed physicians review medical history and determine whether treatment is appropriate.
  • Women-centered care: Treatment discussions can account for concerns involving perimenopause, menopause, and metabolic health.
  • Transparent pricing: Published plan terms explain introductory and recurring costs, including physician care and medication when prescribed.
  • Ongoing support: Injection plans include monthly physician check-ins and care-team messaging.
  • Clear medication disclosures: Compounded preparations are identified separately from FDA-approved treatments, without implying equivalent clinical outcomes.

Majesta's assessment and early-access process allows women to explore their options without guaranteeing treatment or requiring payment before physician approval.

For women considering physician-guided GLP-1 weight management, start your assessment to explore eligibility and learn about the next steps toward informed care.

Before You Consider GLP-1 Treatment

Discuss your medical history, current medications, pregnancy plans, and possible contraindications with a licensed healthcare professional before considering GLP-1 medication. If you are pregnant, planning pregnancy, or using hormonal contraception, ask about medication-specific precautions.

FDA-approved semaglutide and tirzepatide products carry important warnings and contraindications. The prescribing clinician should review these with you, including a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Do not independently start, stop, or change medication without guidance from your prescribing clinician.

When to Get Help Right Away

Seek urgent medical attention for severe or persistent abdominal pain, especially when accompanied by vomiting. These symptoms may indicate pancreatitis or another serious medical problem requiring evaluation.

Call 911 for chest pain, difficulty breathing, fainting, or signs of a severe allergic reaction, such as swelling of the face, lips, tongue, or throat.

Contact your prescribing clinician promptly about persistent vomiting, dehydration, severe gastrointestinal symptoms, or other concerning treatment-related effects.

This article is for informational purposes only and does not constitute medical advice, diagnosis or treatment. It does not recommend starting, stopping or changing any medicine.

Sources checked November 20, 2026.

Frequently Asked Questions

What are the main types of GLP-1 medications available for women's weight loss in 2027?

GLP-1 medications include single-receptor agonists such as semaglutide and dual GIP/GLP-1 receptor agonists such as tirzepatide. FDA-approved products have specific indications and prescribing requirements. Compounded preparations are not FDA-approved final products and are not interchangeable with approved medications. Treatment selection requires individualized physician evaluation.

How does compounded semaglutide or tirzepatide differ from FDA-approved brand-name versions?

Compounded medications are prepared under applicable compounding requirements rather than the FDA approval process used for manufactured prescription medicines. They do not have their own FDA-approved prescribing labels and have not undergone the same premarket safety and effectiveness review. A licensed prescriber must determine whether a compounded preparation is clinically appropriate.

What are the common eligibility criteria for women seeking GLP-1 treatment via telehealth?

Eligibility depends on the medication, approved indication, medical history, and prescribing clinician's assessment. Standard weight-management criteria for some FDA-approved medications include BMI of 30 or greater, or 27 or greater with a qualifying weight-related condition. Completing a telehealth assessment does not guarantee eligibility, treatment approval, or a prescription.

Can GLP-1 medications help women experiencing weight gain during perimenopause or menopause?

GLP-1 medications may be considered for weight management when a woman meets the relevant clinical criteria. However, medication use statistics among women aged 50 to 64 do not establish menopause-specific effectiveness. A licensed physician should evaluate individual health conditions, potential contraindications, medication options, and treatment goals.

How important is physician oversight when getting GLP-1 prescriptions online?

Physician oversight is essential for appropriate GLP-1 treatment. A licensed prescriber evaluates medical history, determines eligibility, reviews contraindications, and monitors treatment-related concerns. Legitimate telehealth services should provide verifiable physician credentials, appropriate pharmacy information, and access to clinical support when medication-related questions or side effects arise.

Sources

  1. 1.Use of Glucagon-Like Peptide-1 Medications and Modified Medication Use Among Adults, United States, 2025 · CDC, Morbidity and Mortality Weekly Report · accessed
  2. 2.New Weight Loss Drugs: GLP-1 Agonist Use and Side Effects in the United States · RAND Corporation · accessed
  3. 3.GLP-1 Drug Prescriptions for Obesity · The Health Foundation · accessed
  4. 4.GLP-1 Injectable Use Among Adults With Diagnosed Diabetes: United States, 2024 · CDC, National Center for Health Statistics · accessed
  5. 5.Year-Two Real-World Analysis of GLP-1 Obesity Treatment Adherence and Persistency · Prime Therapeutics · accessed
  6. 6.Wegovy Prescribing Information · U.S. Food and Drug Administration · accessed
  7. 7.FDA's Concerns With Unapproved GLP-1 Drugs Used for Weight Loss · U.S. Food and Drug Administration · accessed
  8. 8.Compounding and the FDA: Questions and Answers · U.S. Food and Drug Administration · accessed
  9. 9.Prescription Medications to Treat Overweight and Obesity · National Institute of Diabetes and Digestive and Kidney Diseases · accessed
  10. 10.Menopause Transition and Cardiovascular Disease Risk · Circulation, American Heart Association · accessed
  11. 11.Tirzepatide Is an Imbalanced and Biased Dual GIP and GLP-1 Receptor Agonist · PubMed, U.S. National Library of Medicine · accessed
  12. 12.Zepbound Prescribing Information · U.S. Food and Drug Administration · accessed

Ready to Join Early Access?

Join the early access list and we will email you when enrollment opens.

Start Your Assessment